Evidence map›Paper›PMID 41258258›Full record

ArticleScientific reports2025

Explainable and likelihood aware AI framework for MRI-based pixel-level bladder tumour prediction.

Muzammil Khan, Antonius G de Groot, Erik B Cornel, Antoine G van der Heijden, Françoise J Siepel

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Muzammil KhanRobotics and Mechatronics Group, University of Twente, 7522 NB, Enschede, The Netherlands. m.khan@utwente.nl.
Antonius G de GrootRobotics and Mechatronics Group, University of Twente, 7522 NB, Enschede, The Netherlands.
Erik B CornelAndros Clinics Arnhem, 6842 CV, Arnhem, The Netherlands.
Antoine G van der HeijdenRadboud University Medical Center, 6525 GA, Nijmegen, The Netherlands.
Françoise J SiepelRobotics and Mechatronics Group, University of Twente, 7522 NB, Enschede, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bladder tumours (BTs) pose significant clinical challenges due to their high recurrence rates and risk of progression to invasive malignancies, which emphasises the need for early and accurate detection. Magnetic resonance imaging (MRI), with its superior soft tissue contrast, is a potential modality for BT detection. To analyse the MRI scans, artificial intelligence (AI) models are increasingly being leveraged. However, these models are often limited by a scarcity of annotated datasets, challenges in pixel-level tumour prediction, and insufficient transparency in predictions. This study introduces the Explainable and Likelihood-Aware AI (ELAAI) framework, designed to address these limitations. Trained solely on annotated normal bladder MRI scans, ELAAI integrates three novel modules: MFA-Net, a robust multi-scale feature aggregation network for bladder segmentation; a refinement step employing adaptive tolerance technique to enhance segmentation of irregularities; and a single-step likelihood prediction network (SLIP-Net), which is a vision transformer with a novel multi-scale deterministic uncertainty (MSDU) head for tumour likelihood prediction. Rigorous evaluation against state-of-the-art (SOTA) models highlights ELAAI's superior performance, enhancing transparency, and reliability in clinical settings by fostering trust in AI-assisted decision-making.

Indexed as

Artificial IntelligenceMagnetic Resonance ImagingUrinary Bladder NeoplasmsAlgorithmsHumansLikelihood FunctionsUrinary Bladder

Identifiers

PMID41258258
PMCPMC12630720

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.